Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015;32(1):36-44.
doi: 10.3109/10601333.2014.977490. Epub 2014 Nov 13.

Adaptive designs for comparative effectiveness research trials

Affiliations

Adaptive designs for comparative effectiveness research trials

John A Kairalla et al. Clin Res Regul Aff. 2015.

Abstract

Context: Medical and health policy decision makers require improved design and analysis methods for comparative effectiveness research (CER) trials. In CER trials, there may be limited information to guide initial design choices. In general settings, adaptive designs (ADs) have effectively overcome limits on initial information. However, CER trials have fundamental differences from standard clinical trials including population heterogeneity and a vaguer concept of a "minimum clinically meaningful difference".

Objective: To explore the use of a particular form of ADs for comparing treatments within the CER trial context.

Methods: We review the current state of clinical CER, identify areas of CER as particularly strong candidates for application of novel ADs, and illustrate potential usefulness of the designs and methods for two group comparisons.

Results: ADs can stabilize power. The designs ensure adequate power for true effects are at least at clinically significant preplanned effect size, or when variability is larger than expected. The designs allow for sample size savings when the true effect is larger or when variability is smaller than planned.

Conclusion: ADs in CER have great potential to allow trials to successfully and efficiently make important comparisons.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The General Procedure Dashed line and CF are for futility designs only

Similar articles

References

    1. Institute of Medicine. Initial national priorities for comparative effectiveness research. Washington, DC: Natl. Acad. Press; 2009. http://www.nap.edu/catalog/12648.html.
    1. Sox HC, Goodman SN. The methods of comparative effectiveness research. Annu Rev Public Health. 2012;33:425–445. - PubMed
    1. Steinbrook R. Health care and the American Recovery and Reinvestment Act. N Engl J Med. 2009;360:1057–1060. - PubMed
    1. Patient Protection and Affordable Care Act (2010) S. 6301, 111th Congress, 2nd Session. 2010
    1. Patient-Centered Outcomes Research Institute. National priorities for research and research agenda [Internet] Washington (DC): PCORI; 2012. May 2, Available from: http://www.pcori.org/assets/PCORI-National-Priorities-and-Research-Agend.... - PubMed
    2. Luce BR, Kramer JM, Goodman SN, et al. Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med. 2009;151:206–209. - PubMed

LinkOut - more resources